Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan;27(1):40-3.
doi: 10.1681/ASN.2015101125. Epub 2015 Nov 9.

Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT

Glenn M Chertow  1 , Srinivasan Beddhu  2 , Julia B Lewis  3 , Robert D Toto  4 , Alfred K Cheung  2
Affiliations

Managing Hypertension in Patients with CKD: A Marathon, Not a SPRINT

Glenn M Chertow et al. J Am Soc Nephrol. 2016 Jan.

Abstract

In this manuscript, nephrologist-investigators from one of five Clinical Center Networks of the Systolic Blood Pressure Intervention Trial (SPRINT) provide background information and context on the intensity of anti-hypertensive therapy in conjunction with the release of detailed results from SPRINT's primary analysis. The authors highlight published evidence on the safety and efficacy of differing intensities of anti-hypertensive therapy in mild to moderate CKD, where SPRINT will help to inform practice, as well as where gaps in evidence will remain. The authors also challenge the nephrology community to renew its attention and efforts on hypertension clinical care and research.

Keywords: chronic kidney disease; clinical trial; hypertension.

PubMed Disclaimer

References

    1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R, Prospective Studies Collaboration : Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360: 1903–1913, 2002 - PubMed
    1. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators : Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321: 406–412, 1989 - PubMed
    1. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 280: 605–613, 1998 - PubMed
    1. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women’s Health Initiative Investigators : Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349: 523–534, 2003 - PubMed
    1. Gerstein HC, Miller ME, Genuth S, Ismail-Beigi F, Buse JB, Goff DC, Jr., Probstfield JL, Cushman WC, Ginsberg HN, Bigger JT, Grimm RH, Jr., Byington RP, Rosenberg YD, Friedewald WT, ACCORD Study Group : Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 364: 818–828, 2011 - PMC - PubMed

MeSH terms

Substances